Traditional clinical trials often fail in tiny patient populations. Explore new strategies for rethinking evidence generation for ultra-rare diseases. Scientific analyzes results of cerebrospinal fluid in patients with transverse myelitis. [Adobe stock] Developing treatments for ultra-rare diseases presents fundamental challenges for traditional evidence generation. Patient populations for these conditions range from fewer than 10 to up to 1,000, making traditional randomized clinical trial (RCT) designs impractical and possibly unethical. These constraints require sponsors to adopt flexible evidence approaches without compromising the rigor needed to meet regulatory standards for effectiveness. In recent years, the U.S. Food and Drug Administration (FDA) has…
FDA’s RDEP in Context Developing treatments for ultra-rare diseases presents fundamental challenges for traditional evidence generation. Patient populations for these conditions range from fewer than 10 to up to 1,000, making traditional randomized clinical trial (RCT) designs impractical and possibly unethical. These constraints require sponsors to adopt flexible evidence approaches without compromising the rigor needed…
The post Rethinking evidence generation for ultra-rare diseases appeared first on Drug Discovery and Development.
US Pharma Marketing